Celltrion’s Steqeyma (Biosimilar, Stelara) Receives the Health Canada’s Approval to Treat Various Chronic Inflammatory Conditions
Shots:
- Health Canada has approved Steqeyma injection & Steqeyma I.V. (injection, solution for IV infusion), biosimilar versions of Stelara (ustekinumab) to treat adults with moderate to severe active Crohn’s disease & plaque PsO as well as active psoriatic arthritis
- Approval was supported by the P-III trial of Steqeyma vs Stelara, with the 1EP as rate of change in the psoriasis area & severity index for skin symptoms after 52wks. The efficacy was similar in patients who switched to Steqeyma at wk.16
- Steqeyma, an IL-12 & -23 antagonist, is accessible in both IV [130mg/26 mL (5mg/mL) solution in a single-dose vial] & SC (45mg/0.5mL or 90mg/1mL solution in a single-dose, prefilled syringe) formulations
Ref: Businesswire | Image: Celltrion
Related News:- The EC Grants Approval to Celltrion’s Omlyclo (Biosimilar, Xolair)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.